Jan 16 (Reuters) - The U.S. Food and Drug Administration approved Amgen's (AMGN.O), opens new tab combination therapy on Thursday to treat colorectal cancer in patients with a specific gene mutation.

Amgen Inc. sees the potential for 2025 revenues to top Wall Street estimates thanks to growth in cholesterol and cancer drugs ...

Amgen said its experimental weight loss injection helped patients lose up to 20% of their weight on average after a year, with no plateau, in a critical mid-stage trial. But shares of Amgen fell ...

Amgen is cutting the US price of its cholesterol drug Repatha by 60%, following a similar decision by rivals Sanofi and Regeneron earlier this year. Repatha (evolocumab) will now be sold at $5,850 ...

Advisers to the US regulator are to review Amgen's biosimilar of the world's biggest selling drug, AbbVie's Humira, which is facing patent expiry later this year. Amgen said that the FDA's ...

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

Amgen has inaugurated its new drug substance facility in the US after announcing a $1bn further expansion at the North Carolina (NC) site to address increasing demand for its medicines.